Tromsø, Norway - 28 May 2026 - ArcticZymes Technologies ASA (OSE: AZT) today
announced that, following approval at its Annual General Meeting, Dr. Hanna
Pirita Lesch has been elected to the Company's Board of Directors. Dr. Frank
Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected
as a Board member. Sharon Brownlow steps down from the Board after a period of
valued service.

The appointment directly supports the execution of ArcticZymes' strategy:
diversifying into RNA through the build-out of a dedicated RNA enzyme portfolio,
while continuing to strengthen the Company's established position in cell and
gene therapy and broader advanced biomanufacturing.

Supporting diversification into RNA and continued leadership in cell & gene
therapy

Dr. Lesch brings to the Board directly relevant competencies across both
strategic priorities. As Chief Technology Officer of Aurealis Therapeutics, and
previously CTO of Exothera - an international CDMO focused on viral vector and
mRNA-based therapies - she has led technology strategy, platform development,
and CMC for some of Europe's most advanced RNA and gene therapy programs. Her
hands-on experience scaling RNA manufacturing processes supports ArcticZymes'
diversification into the RNA segment, while her deep expertise in viral vector
and ATMP manufacturing reinforces the Company's continued leadership in cell and
gene therapy.

Equally important, Dr. Lesch combines this strategic perspective with a genuine
understanding of the underlying technology and science. She holds a PhD in
Molecular Medicine and an Adjunct Professorship in Biomedicine and Bioprocessing
at the University of Eastern Finland, has authored more than 35 peer-reviewed
publications, and currently chairs the European Society of Gene and Cell
Therapy's Manufacturing Committee. Earlier in her career, as Gene Therapy Unit
Director at the Kuopio Center for Gene and Cell Therapy and R&D Director
at Finvector and FKD Therapies, she contributed to the development of adenoviral
gene therapy products that progressed to marketing approval.

Continuity and stewardship

Dr. Frank Mathias, CEO of Oxford Biomedica and previously CEO of Rentschler
Biopharma and Medigene AG, continues as Chair. Petter Dragesund, an independent
investor and former Senior Partner and Head of Corporate Finance at Pareto
Securities, continues as a Board member. Their re-election ensures continuity of
governance and strategic direction as the Company executes its growth plan.

Thanks to Sharon Brownlow

The Board and Management extend their sincere thanks to Sharon Brownlow, who is
stepping down after contributing valuable life-sciences industry experience
drawn from her senior roles at Catapult and Cobra Biologics. Her perspective has
supported ArcticZymes during an important phase of its development, and the
Company wishes her continued success.

CEO commentary

"Hanna's appointment is a deliberate step to strengthen our Board as we execute
on our strategy - both diversifying into RNA through a dedicated enzyme
portfolio and continuing to build on our leadership in cell and gene therapy.
She brings directly relevant competencies across RNA and viral vector
manufacturing, combined with a deep understanding of the underlying technology
and science - exactly the perspective we need around the Board table as we move
into this next phase," said Michael Akoh, CEO of ArcticZymes Technologies.
"Together with Frank's continued leadership as Chair and Petter's strategic
finance perspective, we have a Board well positioned to support our next phase
of growth. I'd also like to thank Sharon for her contributions during her time
with us - her industry insight has been genuinely valued."

- Ends -

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                    Tel +47 952 90187
                                     [email protected]

About ArcticZymes Technologies
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing, and commercialization of novel recombinant enzymes
for use in molecular research, in vitro diagnostics (IVD), and biomanufacturing.
The company has pioneered salt-active nucleases and continues to develop enzyme
solutions that support efficient and reliable production of advanced
therapeutics.

For more information, please visit the website: www.arcticzymes.com
iable production of advanced\
therapeutics.\
\
For more information\, please visit the website: www.arcticzymes.com\